Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 501–600 of 1,003
Regulation of food intake by gastrointestinal hormones
Baynes, K. C., Dhillo, W. S., & Bloom, S. R. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000245537.43142.63 · Cited by 53
Self-citationGhitza, U. E., Nair, S. G., Golden, S. A., Gray, S. M., Uejima, J. L., Bossert, J. M., & Shaham, Y. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5405-06.2007 · Cited by 54
“Systemic PYY3-36 injections decrease food intake in mice, rats, monkeys, and humans (Batterham et al., 2002, 2003; Moran et al., 2005; Chelikani et al., 2006) [but see Tschop et al. (2004) and Boggiano et al. (2005) for different results].”
ResultRegulation of Peptide YY Levels by Age, Hormonal, and Nutritional Status
Tovar, S. A., Seoane, L. M., Caminos, J. E., Nogueiras, R., Casanueva, F. F., & Diéguez, C. (2004) · Obesity Research · doi:10.1038/oby.2004.244 · Cited by 56
Does gut hormone PYY3–36 decrease food intake in rodents? (reply)
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2004) · Nature · doi:10.1038/nature02666 · Cited by 58
Self-citationFenske, W. K., Bueter, M., Miras, A. D., Ghatei, M. A., Bloom, S. R., & le Roux, C. W. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.126 · Cited by 57
“PYY-like immunoreactivity was measured with a specific and sensitive radioimmunoassay, which measures, both the full length (PYY1–36) and the fragment (PYY3–36)”
MethodSelf-citationFeinle‐Bisset, C. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.021 · Cited by 54
“However, the limited available evidence indicates that the appetite and energy intake responses to intravenous CCK and PYY do not differ between obese and lean individuals [10,84], although only one hormone dose was used in each study, and the study using CCK was performed in females only, and did not control for any…”
Xia, F., Wen, L., Ge, B., Li, Y., Li, F., & Zhou, B. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i8.1146 · Cited by 58
The PP-Fold Solution Structure of Human Polypeptide YY and Human PYY3-36 As Determined by NMR,
Nygaard, R., Nielbo, S., Schwartz, T. W., & Poulsen, F. M. (2006) · Biochemistry · doi:10.1021/bi060359l · Cited by 51
Energy Metabolic Profile of Mice after Chronic Activation of Central NPY Y1, Y2, or Y5 Receptors**
Henry, M., Ghibaudi, L., Gao, J., & Hwa, J. J. (2005) · Obesity Research · doi:10.1038/oby.2005.6 · Cited by 51
Neary, M. T., & Batterham, R. L. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.024 · Cited by 60
Self-citationThe satiety hormone peptide YY as a regulator of appetite
Vincent, R. P., & le Roux, C. W. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048488 · Cited by 51
Lin, E.-J. D., Sainsbury, A., Lee, N. J., Boey, D., Couzens, M., Enriquez, R., Slack, K., Bland, R., During, M. J., & Herzog, H. (2006) · Endocrinology · doi:10.1210/en.2006-0097 · Cited by 51
“Moreover, food intake in obese human subjects was shown to be inhibited by a preferential Y2/Y5 receptor agonist (PYY)3–36 (31) and ICV administration of PYY3–36 or other Y2 receptor agonists has been shown to reduce feeding and body weight in rodents (19, 32, 33).”
BackgroundHormonal and Metabolic Consequences of Childhood Obesity
Artz, E., Haqq, A. M., & Freemark, M. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.04.004 · Cited by 56
Appetite control after weight loss: what is the role of bloodborne peptides?
Doucet, É., & Cameron, J. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-019 · Cited by 51
Gut Microbiota of Nonalcoholic Fatty Liver Disease
Abdou, R., Zhu, L., Baker, R. D., & Baker, S. S. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4045-1 · Cited by 55
Kil, D. Y., & Swanson, K. S. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.10.004 · Cited by 64
“GLP-1 response, fasting and postprandial plasma PYY-2 concentrations have been reported to be lower in obese than in lean humans.(102,114) Postprandial plasma PYY-2 concentrations, which are typically increased in normal-weight subjects after a meal, were blunted in obese subjects.”
Ellacott, K. L. J., Halatchev, I. G., & Cone, R. D. (2005) · Peptides · doi:10.1016/j.peptides.2005.02.031 · Cited by 54
Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms
Vetter, M. L., Ritter, S., Wadden, T. A., & Sarwer, D. B. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.4.200 · Cited by 54
Østergaard, S., Paulsson, J. F., Kofoed, J., Zosel, F., Olsen, J., Jeppesen, C. B., Spetzler, J. C., Ynddal, L., Schleiss, L. G., Christoffersen, B. Ø., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00654-3 · Cited by 54
Gut Peptides: Targets for Antiobesity Drug Development?
Moran, T. H., & Dailey, M. J. (2009) · Endocrinology · doi:10.1210/en.2009-0003 · Cited by 49
“Both peripheral and central sites of action for PYY(3-36) for inhibiting food intake have been proposed.”
BackgroundInfluentialRigamonti, A. E., Piscitelli, F., Aveta, T., Agosti, F., Col, A. D., Bini, S., Cella, S. G., Marzo, V. D., & Sartório, A. (2015) · Food & Nutrition Research · doi:10.3402/fnr.v59.29678 · Cited by 53
“Therefore, obese individuals, having lower circulating PYY and insensitivity to GLP-1 (24, 25), would have, at least theoretically, an increased activity in the striatum, insula, and OFC during exposure to food.”
BackgroundEfficacy of Dietary and Supplementation Interventions for Individuals with Type 2 Diabetes
Lewgood, J., Oliveira, B., Korzepa, M., Forbes, S. C., Little, J. P., Breen, L., Bailie, R., & Candow, D. G. (2021) · Nutrients · doi:10.3390/nu13072378 · Cited by 57
Gut Hormones: A Weight Off Your Mind
Gardiner, J. V., Jayasena, C. N., & Bloom, S. R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01729.x · Cited by 48
Self-citationDigestion and Absorption of Nutrients and Vitamins
Farrell, J. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00100-1 · Cited by 52
Beglinger, C., Poller, B., Arbit, E., Ganzoni, C., Gass, S., Gomez-Orellana, I., & Drewe, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.35 · Cited by 48
Zachariah, S., Sheldon, B., Shojaee‐Moradie, F., Jackson, N. C., Backhouse, K., Johnsen, S., Jones, R. H., Umpleby, A. M., & Russell-Jones, D. L. (2011) · Diabetes Care · doi:10.2337/dc11-0098 · Cited by 55
“PP-binding sites have been demonstrated in the area postrema, and the activation of neurons in the area postrema after PP administration suggests that PP has a central effect on satiety (19).”
BackgroundPeptides and Their Potential Role in the Treatment of Diabetes and Obesity
Greenwood, H. C., Bloom, S. R., & Murphy, K. G. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.355 · Cited by 48
“Peripheral administration of PYY3-36 reduces food intake in wild-type rodents and lean and obese humans, but not in mice lacking the Y2 receptor [81, 88].”
BackgroundSelf-citationLiu, Y., Heath, A. M., Galland, B. C., Rehrer, N. J., Drummond, L., Wu, X., Bell, T. J., Lawley, B., Sims, I. M., & Tannock, G. W. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.01905-19 · Cited by 55
Ratliff, J. C., Mutungi, G., Puglisi, M. J., Volek, J. S., & Fernández, M. L. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.03.007 · Cited by 54
“Circulating PP and PYYare found in lower levels in obese individuals [54], and infusion of these peptides reduces food intake in humans [55,56].”
BackgroundReversible PEGylation of peptide YY3‐36 prolongs its inhibition of food intake in mice
Shechter, Y., Tsubery, H., Mironchik, M., Rubinstein, M., & Fridkin, M. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.044 · Cited by 48
“Several studies have demonstrated that peripheral administration of PYY3-36 inhibits food intake in humans, mice, and rats following a 24 h fast [5–7].”
BackgroundMonnier, L., Schlienger, J.-L., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.002 · Cited by 47
The regulation of gastric ghrelin secretion
Nunez‐Salces, M., Li, H., Feinle‐Bisset, C., Young, R. L., & Page, A. J. (2020) · Acta Physiologica · doi:10.1111/apha.13588 · Cited by 49
Yadav, J., Liang, T., Qin, T., Nathan, N., Schwenger, K. J. P., Pickel, L., Xie, L., Lei, H., Winer, D. A., Maughan, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101051 · Cited by 57
Katz, L., Gambale, J. J., Rothenberg, P., Vanapalli, S. R., Vaccaro, N. M., Xi, L., Polidori, D., Vets, E., Sarich, T. C., & Stein, P. P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.169 · Cited by 51
Estrogen and peptide YY are associated with bone mineral density in premenopausal exercising women
Scheid, J. L., Toombs, R. J., Ducher, G., Gibbs, J. C., Williams, N. I., & Souza, M. J. D. (2011) · Bone · doi:10.1016/j.bone.2011.04.011 · Cited by 51
“PYY acts centrally to inhibit neuropeptide Y (NPY) and activate the proopiomelanocortin (POMC) neurons in the arcuate nucleus resulting in a reduction in food intake [19].”
BackgroundNeuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat
Zengin, A., Zhang, L., Herzog, H., Baldock, P. A. J., & Sainsbury, A. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.02.004 · Cited by 55
The effect of bariatric surgery on gut hormones that alter appetite
Pournaras, D. J., & le Roux, C. W. (2009) · Diabetes & Metabolism · doi:10.1016/s1262-3636(09)73457-3 · Cited by 57
“It induces satiety and reduce nutrient intake in both the obese and the non-obese, however obese individuals appear to have a PYY deficiency that could affect satiety signals and could thus reinforce obesity [9-11].”
BackgroundSainsbury, A., Bergen, H., Boey, D., Bamming, D., Cooney, G. J., Lin, S., Couzens, M., Stroth, N., Lee, N. J., Lindner, D., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0472 · Cited by 48
“Moreover, circulating peptide YY from the gut and its truncated form peptide YY3–36 (a preferential Y2 agonist) have been shown to reduce food intake, adiposity, and/or body weight after short- or longterm administration to lean or obese rodents or humans (1,11,12).”
Background(2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.089540 · Cited by 47
Meal‐related Changes in Ghrelin, Peptide YY, and Appetite in Normal Weight and Overweight Children
Lomenick, J. P., Clasey, J. L., & Anderson, J. W. (2008) · Obesity · doi:10.1038/oby.2007.129 · Cited by 51
“However, in studies where a change in ghrelin was observed following a meal (5,8,9) and in studies of PYY (7,8,28), the difference from baseline to 60 min was similar or more pronounced than at 15 or 30 min.”
BackgroundMethodResultInfluentialBrennan, I. M., Little, T. J., Feltrin, K. L., Smout, A. J. P. M., Wishart, J. M., Horowitz, M., & Feinle-Bisset, C. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90791.2008 · Cited by 45
“For example, intravenous PYY suppresses ghrelin in humans (3), and in vitro studies in rodents suggest that GLP-1 also has this effect (28).”
Regulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 56
The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes
Guida, C., Stephen, S., Guitton, R., & Ramracheya, R. D. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.005 · Cited by 49
“The inhibition of DPP-IV, the proteolytic enzyme responsible for the degradation of GLP-1 and PYY, constitutes an effective therapy for T2D, but the benefits have so far been attributed to the prolongation of active GLP-1 alone.”
BackgroundInfluentialPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“concentrations are significantly lower in T2D [121] and obesity [122] suggesting the PYY is not involved in the impaired insulin secretion.”
Physiology of ghrelin and related peptides
Anderson, L. L., Jeftinija, S., Scanes, C. G., Stromer, M. H., Lee, J.-S., Jeftinija, K., & Glavaski‐Joksimovic, A. (2005) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2005.02.033 · Cited by 51
Anorexigenic Effects of GLP-1 and Its Analogues
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_8 · Cited by 50
Bariatric Embolization of the Gastric Arteries for the Treatment of Obesity
Weiss, C. R., Gunn, A. J., Kim, C., Paxton, B. E., Kraitchman, D. L., & Arepally, A. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.01.017 · Cited by 45
“For example, one study (19) found that the peripheral infusion of PYY3-36 reduced caloric intake in lean and obese patients by as much as 31%.”
BackgroundWu, W., Zhou, H.-R., He, K., Pan, X., Sugita‐Konishi, Y., Watanabe, M., Zhang, H., & Pestka, J. J. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft335 · Cited by 45
“Peripheral administration of PYY3-36 induces satiety in many species including humans, nonhuman primates and rodents (Batterham et al., 2002; Batterham et al., 2003a; Batterham et al., 2003b).”
BackgroundThe neurohormonal regulation of energy intake in relation to bariatric surgery for obesity
Ochner, C. N., Gibson, C., Carnell, S., Dambkowski, C., & Geliebter, A. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.04.032 · Cited by 45
“[73] infused PYY3–36 at a rate designed to mimic thatwhichwould be expected in response to ameal and assessed brain activation concurrently, using fMRI.”
Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition
Epstein, S., Defeudis, G., Manfrini, S., Napoli, N., & Pozzilli, P. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3454-x · Cited by 48
“The linkage between PYY and bone metabolism suggests a negative correlation between PYYand bone formation as levels are low in obese patients [90, 91] in which there is a higher BMD [92].”
BackgroundPossible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS)
El‐Salhy, M., Hatlebakk, J. G., & Hausken, T. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.101973 · Cited by 52
“Moreover, the plasma concentration of PYY is low in obese subjects (Batterham et al., 2003; Batterham et al., 2002).”
Wang, X., Liu, F., Cui, Y., Yin, Y., Li, S., & Li, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07258 · Cited by 47
Yamada, T., Oka, Y., & Katagiri, H. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.006 · Cited by 51
Dagbasi, A., Lett, A. M., Murphy, K., & Frost, G. (2020) · Proceedings of the Nutrition Society · doi:10.1017/s0029665120006941 · Cited by 44
“Indeed, peripheral administration of PYY and GLP-1 has been shown to suppress appetite and reduce food intake in both rodents and lean and obese human subjects((62,64,85,86)).”
Self-citationManagement approaches for pediatric obesity
Miller, J. L., & Silverstein, J. H. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0669 · Cited by 60
“PYY levels are low in obese individuals, and the administration of this hormone reduces food intake”
BackgroundPossible Mechanisms of Circulating PYY-Induced Satiation in Male Rats
Stadlbauer, U., Arnold, M., Weber, E., & Langhans, W. (2013) · Endocrinology · doi:10.1210/en.2012-1956 · Cited by 45
Tsouristakis, A. I., Febres, G., McMahon, D. J., Tchang, B. G., Conwell, I. M., Tsang, A., Ahmed, L., Bessler, M., & Körner, J. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04111-z · Cited by 49
Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2022) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 40
“Peripheral administration of PYY3–36 reduces food intake and body weight in experimental animals (Batterham et al. 2003; Challis et al. 2003; Koegler et al. 2005; Abdel-Hamid et al. 2019).”
BackgroundNeuroendocrine control of food intake
Park, A. J., & Bloom, S. R. (2005) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000153358.05901.3f · Cited by 44
“PYY 3-36 은 렙틴과는 달리 비만한 사람에서 저항성을 나타내지 않으 며 마른 사람에서와 마찬가지의 음식 섭취 억제 효과를 보 인다[36].”
Self-citationMetformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes
English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., Eccleston, D., Bloom, S. R., Ghatei, M. A., & Wilding, J. P. H. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.681 · Cited by 44
“Both fasting concentrations and postprandial response appear to decrease in obese subjects [9].”
BackgroundMethodSelf-citationEmerging aspects of pharmacotherapy for obesity and metabolic syndrome
Nisoli, E., & Carruba, M. O. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.02.004 · Cited by 47
“[103] have found more recently that a single infusion of PYY3–36, as compared with an infusion of saline, reduced appetite and food consumption by approximately 30% at an all-you-want-to-eat buffet lunch provided 2 h after the infusion.”
BackgroundZhang, Y., Rahematpura, S., Ragnini, K., Moreno, A., Stecyk, K. S., Kahng, M. W., Milliken, B. T., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108599 · Cited by 44
Visvanathan, R. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.04.012 · Cited by 48
“Intravenous infusion of PYY that produces postprandial blood levels has been shown to reduce short-term food intake in normalweight andobese adults (<50 years) by approximately 30%, but the results of this 1 study have not been reproduced.(40) It is, therefore, unclear whether PYY truly contributes to the development…”
ResultPazos, Y., Alvarez, C. J. P., Camiña, J. P., & Casanueva, F. F. (2007) · Growth Factors · doi:10.1080/08977190801889313 · Cited by 43
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 51
Zhang, N., Yuan, C., Li, Z., Li, J., Li, X., Li, C., Li, R. Q., & Wang, S. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ec41ed · Cited by 43
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
“tion in food intake in rodents and humans [82].”
BackgroundLeptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats
Unniappan, S., & Kieffer, T. J. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00234.2007 · Cited by 51
Exercise in rats does not alter hypothalamic AMP-activated protein kinase activity
Andersson-Hall, U. K., Treebak, J. T., Nielsen, J. N., Smith, K. L., Abbott, C. R., Small, C. J., Carling, D., & Richter, E. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.027 · Cited by 46
“PYY-like IR was measured using a specific and sensitive RIA, as previously described [21].”
MethodLower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits
Sileno, A. P., Brandt, G., Spann, B. M., & Quay, S. C. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803067 · Cited by 44
Why Do Patients Lose Weight after Roux-en-Y Gastric Bypass?
le Roux, C. W., & Bloom, S. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2211 · Cited by 43
Self-citationEstablished and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000612 · Cited by 42
“Much of the initial therapeutic focus on PYY revolved around PYY (3–36) peptides, and related NPYR2 activation, for the potential management of obesity [17,19,22].”
BackgroundPeripheral neural targets in obesity
Page, A. J., Symonds, E., Peiris, M., Blackshaw, L. A., & Young, R. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01951.x · Cited by 43
“Despite this generalized attenuation in GI peptide release, the anorectic effects of exogenously administered CCK, PYY and GLP-1 appear to be preserved in obese individuals (Flint et al., 2001; Batterham et al., 2003).”
BackgroundRiediger, T. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s0029665112000778 · Cited by 42
“Basal and postprandial PYY(3–36) levels are decreased in obese human subjects and rodents((45)).”
BackgroundShrestha, Y. B., Wickwire, K., & Giraudo, S. Q. (2009) · Peptides · doi:10.1016/j.peptides.2009.02.001 · Cited by 42
“Also a fat diet can activate PYY and GLP-1, and both have been shown to decrease ghrelin levels in vivo and from isolated stomach [4,24].”
BackgroundWeickert, M. O., Reimann, M., Otto, B., Hall, W. L., Vafeiadou, K., Hallund, J., Ferrari, M., Talbot, D. C. S., Branca, F., Bügel, S., et al. (2006) · Journal of Negative Results in BioMedicine · doi:10.1186/1477-5751-5-11 · Cited by 48
“[3-36] in supraphysiological [24,25], but not in physiological doses [25] reduces appetite and food intake.”
BackgroundExercise, Appetite and Weight Control: Are There Differences between Men and Women?
Thackray, A. E., Deighton, K., King, J. A., & Stensel, D. J. (2016) · Nutrients · doi:10.3390/nu8090583 · Cited by 52
Grembi, J. A., Nguyen, L. H., Haggerty, T. D., Gardner, C. D., Holmes, S., & Parsonnet, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-58000-y · Cited by 48
“facilitated responsiveness to the increased carbohydrates and fiber consumed on the low-fat diet 229 [24], making the transition to the new diet easier for subjects in ways that aided adherence through 230 appetite suppression [33, 39, 8, 25, 12, 3, 2].”
BackgroundMoffett, R. C., Docherty, N. G., & le Roux, C. W. (2020) · Appetite · doi:10.1016/j.appet.2020.104807 · Cited by 45
Dumont, Y., Moyse, E., Fournier, A., & Quirion, R. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9007-9 · Cited by 43
“For example, peripheral administration of PYY(3–36) (Batterham et al. 2002; Batterham et al. 2003a) and PP (Batterham et al. 2003b) decreased food intake in rat and human.”
BackgroundDose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2006) · Peptides · doi:10.1016/j.peptides.2006.08.001 · Cited by 42
Obesity: basic science and medical aspects relevant to anaesthetists
Cheah, M. H., & Kam, P. C. A. (2005) · Anaesthesia · doi:10.1111/j.1365-2044.2005.04229.x · Cited by 43
Physiological response of the human pancreas to enteral and parenteral feeding
O’Keefe, S. J. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241675.63041.ca · Cited by 42
Xanthakos, S. A. (2008) · Pathophysiology · doi:10.1016/j.pathophys.2008.04.005 · Cited by 45
“Nonetheless, intravenous infusion of PYY3–36 in 12 obese nd 12 lean human subjects in a placebo-controlled doublelinded, crossover study let to a 30% decrease in food intake n both obese and lean subjects at a single meal and a signifcant decrease in cumulative 24 h caloric intake [99].”
BackgroundChen, Y., Shen, Y., Pandit, N. P., Fu, J., Li, D., & Li, J. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.03.029 · Cited by 41
“While the appetite regulatory effect of PYY is controversial in some cases (McGowan and Bloom, 2004), the consensus derived from a range of mammalian models have demonstrated that PYY reduce food intake (Batterham et al., 2003; Challis et al., 2003; Koda et al., 2005; Ueno et al., 2008).”
ResultNew Targets for Drug Treatment of Obesity
Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 48
Melanocortin neurons: Multiple routes to regulation of metabolism
Shen, W.-J., Yao, T. S., Kong, X., Williams, K. W., & Liu, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.05.007 · Cited by 53
“Ghrelin stimulates food intake and increases fat mass [69,150,151] partly by activating GHSR in the NPY/AgRP neurons within ARC [152,153].”
InfluentialInterleukin-17 acts in the hypothalamus reducing food intake
Nogueira, G. A. S., Solon, C., Carraro, R. S., Engel, D. F., Ramalho, A. F. S., Sidarta-Oliveira, D., Gaspar, R. S., Bombassaro, B., Vasques, A. C. J., Geloneze, B., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.12.012 · Cited by 43
Resistin-Like Molecule α Decreases Glucose Tolerance during Intestinal Inflammation
Munitz, A., Seidu, L., Cole, E. T., Ahrens, R., Hogan, S. P., & Rothenberg, M. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803130 · Cited by 41
“In particular, PYY has been found to be up-regulated in the serum of humans and mice with diet-induced obesity (31, 32).”
BackgroundHill, B. R., De Souza, M. J., & Williams, N. I. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00171.2011 · Cited by 41
“Fasting as well as postprandial PYY concentrations have been shown to be depressed in obese and elevated in energydeficient women (3, 13, 20, 31).”
BackgroundGhrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children
Maffeis, C., Bonadonna, R. C., Consolaro, A., Vettor, R., Banzato, C., Silvagni, D., Bogoni, G., Pellegrino, M., & Tatò, L. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02055 · Cited by 46
“For instance, peptide YY infusion has been shown to reduce fasting ghrelin levels ( 36 ) and ghrelin interferes with cortisol secretion, thereby increasing its concentration (37).”
BackgroundEnteroendocrine cell differentiation and function in the intestine
Sanchez, J. G., Enriquez, J. R., & Wells, J. M. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000709 · Cited by 41
Adipose tissue in cortisol excess: What Cushing’s syndrome can teach us?
Bavaresco, A., Mazzeo, P., Lazzara, M., & Barbot, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116137 · Cited by 45
Lewis, H. B., Ahern, A. L., Solis‐Trapala, I., Walker, C. G., Reimann, F. M., Gribble, F. M., & Jebb, S. A. (2015) · Obesity · doi:10.1002/oby.21105 · Cited by 44
“In contrast with the known function of PYY, where exogenous administration reduces EI (17,33,34), there was a small but significant positive effect of AUC and prelunch PYY on subsequent EI.”
ResultLessons Learned from Gastric Bypass Operations in Rats
Seyfried, F., le Roux, C. W., & Bueter, M. (2011) · Obesity Facts · doi:10.1159/000327301 · Cited by 47
Belinova, L., Kahleová, H., Malínská, H., Topolčan, O., Windrichová, J., Oliyarnyk, O., Kazdová, L., Hill, M., & Pelikánová, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174820 · Cited by 44
Weight Loss and Appetite Control in Women
Hintze, L. J., Mahmoodianfard, S., Auguste, C. B., & Doucet, É. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0273-8 · Cited by 48
Peiris, M., Aktar, R., Reed, D. E., Cibert‐Goton, V., Zdanaviciene, A., Halder, W., Robinow, A. D., Corke, S., Dogra, H., Knowles, C. H., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323219 · Cited by 44
“5 6 We show that colonic EEC are equipped with multiple receptors for nutrients endogenous and exogenous to the colon, which together can trigger a potent endocrine response.”
Endocrine and metabolic response to gastric bypass
Saliba, J., Wattacheril, J. J., & Abumrad, N. N. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832e1b14 · Cited by 43
Yang, N., Liu, X., Ding, E. L., Xu, M., Wu, S., Liu, L., Sun, X., & Hu, F. B. (2009) · Journal of Nutrition · doi:10.3945/jn.109.104406 · Cited by 50
“In humans, lower circulating PYY concentrations have been reported in obese individuals (17), but whether they play a role in the etiology of obesity remains controversial (24,25).”
BackgroundResult
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.